ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
To determine efficacy in the delivery of chronomodulated chemotherapy.
Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer|
- The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen. [ Time Frame: 2 years ]
|Study Start Date:||October 2006|
|Study Completion Date:||September 2007|
The purpose of this study is to determine if treatment with 5-Fluorouracil, leucovorin, oxaliplatin, and Avastin will cause colorectal tumor cells to shrink or disappear. The study will also determine the safety of these drugs when given together and the quality of life of the patients who are enrolled in the study.
It is thought that these drugs will be better tolerated if they are chronomodulated, i.e., if they are given at certain times of day rather than as a continuous infusion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00385021
|United States, Oklahoma|
|Cancer Treatment Centers of America at Southwestern Regional Medical Center, Inc.|
|Tulsa, Oklahoma, United States, 74133|
|Principal Investigator:||Petra Ketterl, MD||Cancer Treatment Centers of America at Southwestern Regional Medical Center, Inc.|